Invited
Controlled Proteostasis: PROTAC-mediated protein degradation as a new therapeutic modality

The ability to control protein levels using PROTACs is changing how drugs are being developed and is expanding our concept of the druggable target space. Moreover, PROTACs offer the advantages of siRNA but with more favorable pharmaceutical properties (ADME, biodistribution, routes of administration). For the past 20 years, my lab has pioneered the development of this new modality from concept to clinical trials. Here I will describe the current and future trends in this fast-paced, exciting new therapeutic field.